



Supplementary Figure 1


a



b




c




Supplementary Figure 2


a



b




c




Supplementary Figure 3


a



b





c




Supplementary Figure 4


a




b



c





+ (AKT3)






- (No primary Antibody)

Supplementary Figure 5


a



b



c






TFAP2B

Nevus




Primary melanoma

Metastasis

OVOL1




EPHX3




Supplementary Figure 7


OLIG3 - Nevus




OLIG3 – Primary melanoma




OLIG3 – Metastasis





AKT3 – Primary melanoma




TFAP2B – Primary melanoma



Supplementary Figure 8






Supplementary Figure 9






Supplementary Figure 10


a



b




Patients features (N = 65)



Supplementary Figure 11

PON3 in TCGA



Supplementary Figure 12

OVOL1






EPHX3

OLIG3






AKT3

TFAP2B

Low







High



Supplementary Figure 13

a



b

